[Lymphokine-activated killer cell adoptive immunotherapy for cancer treatment and its significance].
New culture system, CDCS-T1, was developed for clinical conduction of lymphokine-activated killer (LAK) cell adoptive immunotherapy (AIT). Advanced or recurrent cancer patients of digestive tract were treated with AIT with LAK cells generated by CDCS-T1 in combination with plasma exchange. Partial responses were shown in 10 to 20% of patients treated. Long survival was found in some responders, indicating the significance of LAK therapy for cancer treatment. AIT with LAK cell transfer was also conducted in patients with esophageal cancer as postoperative adjuvant therapy. Better restoration of postoperative depression of immunological parameters was found in patients with postoperative LAK cell transfer. It is suggested that postoperative LAK cell transfer is a good candidate for adjuvant immunotherapy for cancer treatment.
Toge
T
T
Department of Surgery, Hiroshima University, Japan.
Yamaguchi
Y
Y
D000368:Aged; D006528:Carcinoma, Hepatocellular / Q000628:therapy; D002292:Carcinoma, Renal Cell / Q000628:therapy; D002478:Cells, Cultured; D003131:Combined Modality Therapy; D003584:Cytological Techniques; D004938:Esophageal Neoplasms / Q000276:immunology / Q000628:therapy; D005260:Female; D006801:Humans; D016219:Immunotherapy, Adoptive; D007376:Interleukin-2 / Q000627:therapeutic use; D007680:Kidney Neoplasms / Q000628:therapy; D015979:Killer Cells, Lymphokine-Activated / Q000637:transplantation*; D008113:Liver Neoplasms / Q000628:therapy; D008297:Male; D008875:Middle Aged; D009369:Neoplasms / Q000628:therapy*
D007376:Interleukin-2